The status of patentability for new dosage regimes in Mexico is unclear, but there have been some positive signs, says Pablo Fuentes.
Brazil’s IP system has struggled to keep pace with its economic growth, but as Otto Licks and Marcela Trigo explain, there are some promising signs.
The system governing preliminary injunctions for pharmaceutical patent infringement should be revised to stave off potential frivolous cases, say Hedwig Lindner and Manuel Morante.
LSIPR talks to Matt McBride about how Science IP can help businesses ensure their patent plans get off to the best possible start.
When introducing medicinal products to any market, the strength of the trademark is crucial. But the Mexican system requires getting trademark approval from two different authorities.
Russia’s life sciences industry is growing rapidly, say Vadim Chagin and Maria Nilova.
For the first time in the history of the Indian patent system, a compulsory licence has been granted. Archana Shanker considers the implications.
For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs.
When it comes to life sciences, Boston is out on its own. LSIPR takes a look at innovation in the Olde Towne.
The America Invents Act was signed into law in September 2011, and many biotech companies are still trying to make sense of the new legislation. Eldora Ellison and Eric Steffe consider one of the most important changes.